Editas Medicine (EDIT) News Today $1.22 -0.02 (-1.61%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Editas Medicine, Inc. (NASDAQ:EDIT) Short Interest UpdateEditas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) was the recipient of a significant growth in short interest in December. As of December 31st, there was short interest totalling 18,210,000 shares, a growth of 7.6% from the December 15th total of 16,930,000 shares. Based on an average daily trading volume, of 2,620,000 shares, the short-interest ratio is currently 7.0 days.January 19 at 6:46 PM | marketbeat.comBank of America Securities Sticks to Their Sell Rating for Editas Medicine (EDIT)January 16, 2025 | markets.businessinsider.comEditas Medicine, Inc. (EDIT) 43rd Annual JPMorgan Healthcare Conference - (Transcript)January 15, 2025 | seekingalpha.comEditas Medicine: Strategic Ambitions and Cautious Optimism in Gene-Editing AdvancementsJanuary 15, 2025 | markets.businessinsider.comEditas Medicine (EDIT) Receives a Buy from TD CowenJanuary 14, 2025 | markets.businessinsider.comEditas Medicine announces strategic priorities, 2025 key milestonesJanuary 13, 2025 | markets.businessinsider.comEditas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic PrioritiesJanuary 13, 2025 | globenewswire.comIntellia Therapeutics (NTLA) Receives a Buy from Evercore ISIJanuary 10, 2025 | markets.businessinsider.comGene editing stocks drop as Intellia announces layoffsJanuary 10, 2025 | msn.comEditas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 6, 2025 | globenewswire.comShort Interest in Editas Medicine, Inc. (NASDAQ:EDIT) Rises By 5.4%Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) was the recipient of a large growth in short interest during the month of December. As of December 15th, there was short interest totalling 16,930,000 shares, a growth of 5.4% from the November 30th total of 16,060,000 shares. Based on an average daily volume of 2,450,000 shares, the short-interest ratio is presently 6.9 days.January 1, 2025 | marketbeat.comSangamo Biosciences: Hold Rating Amidst Funding Challenges and Strategic UncertaintyDecember 31, 2024 | markets.businessinsider.comWhy Is Editas Medicine, Inc. (EDIT) Among the Top CRISPR Stocks to Invest In?December 30, 2024 | msn.comEditas Medicine, Inc. (NASDAQ:EDIT) Shares Sold by State Street CorpState Street Corp reduced its stake in shares of Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) by 46.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,462,022 shares of the company's stock after seDecember 28, 2024 | marketbeat.comEditas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Rating of "Hold" from BrokeragesEditas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) has been given an average rating of "Hold" by the fourteen analysts that are covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have assigneDecember 27, 2024 | marketbeat.comThree Kendall Square buildings sold to lab heavyweight for $250MDecember 23, 2024 | bizjournals.comJP Morgan Downgrades Editas Medicine (EDIT)December 17, 2024 | msn.comEditas Medicine price target lowered to $5 from $7 at Evercore ISIDecember 16, 2024 | markets.businessinsider.comCambridge company is laying of 180 people, 65% of its workforceDecember 16, 2024 | msn.comEvercore ISI Lowers Editas Medicine (NASDAQ:EDIT) Price Target to $5.00Evercore ISI decreased their price objective on shares of Editas Medicine from $7.00 to $5.00 and set an "outperform" rating on the stock in a report on Monday.December 16, 2024 | marketbeat.comJPMorgan Chase & Co. Downgrades Editas Medicine (NASDAQ:EDIT) to UnderweightJPMorgan Chase & Co. downgraded shares of Editas Medicine from a "neutral" rating to an "underweight" rating in a research note on Monday.December 16, 2024 | marketbeat.comStifel Downgrades Editas Medicine (EDIT)December 15, 2024 | msn.comChardan Capital Downgrades Editas Medicine (EDIT)December 14, 2024 | msn.comEditas Medicine: Strategic Shift and Uncertainties Prompt Hold RatingDecember 14, 2024 | markets.businessinsider.comEditas Medicine Maintains Hold Rating Amid Strategic Shifts and Financial ChallengesDecember 14, 2024 | markets.businessinsider.comGene-editing pioneer Editas lays off more than half its employeesDecember 14, 2024 | bizjournals.comBrokerages downgrade gene editing company Editas to 'hold', shares slump 23%December 14, 2024 | msn.comRoyal Bank of Canada Issues Pessimistic Forecast for Editas Medicine (NASDAQ:EDIT) Stock PriceRoyal Bank of Canada decreased their price target on shares of Editas Medicine from $5.00 to $4.00 and set a "sector perform" rating on the stock in a report on Friday.December 13, 2024 | marketbeat.comBarclays Cuts Editas Medicine (NASDAQ:EDIT) Price Target to $3.00Barclays reduced their target price on Editas Medicine from $5.00 to $3.00 and set an "equal weight" rating for the company in a research report on Friday.December 13, 2024 | marketbeat.comEditas Medicine: Navigating Uncertainty with a Hold Rating Amid Strategic Shifts and Development ChallengesDecember 13, 2024 | markets.businessinsider.comCautious Outlook for Editas Medicine Amid Strategic Shift and Competitive ChallengesDecember 13, 2024 | markets.businessinsider.comEditas to cut 65% of workforce in strategy shift; shelves lead gene-editing programDecember 13, 2024 | msn.comEditas Medicine's (EDIT) "Neutral" Rating Reaffirmed at Chardan CapitalChardan Capital reissued a "neutral" rating on shares of Editas Medicine in a research report on Friday.December 13, 2024 | marketbeat.comRobert W. Baird Cuts Editas Medicine (NASDAQ:EDIT) Price Target to $8.00Robert W. Baird lowered their target price on shares of Editas Medicine from $10.00 to $8.00 and set an "outperform" rating for the company in a report on Friday.December 13, 2024 | marketbeat.comEditas Medicine (NASDAQ:EDIT) Cut to "Hold" at Stifel NicolausStifel Nicolaus lowered Editas Medicine from a "buy" rating to a "hold" rating and cut their price target for the stock from $11.00 to $3.00 in a report on Friday.December 13, 2024 | marketbeat.comEditas Medicine (NASDAQ:EDIT) Downgraded to Hold Rating by Truist FinancialTruist Financial downgraded shares of Editas Medicine from a "buy" rating to a "hold" rating in a research report on Friday.December 13, 2024 | marketbeat.comEditas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026December 13, 2024 | benzinga.comEditas to lay off staff after search for sickle cell partner comes up emptyDecember 12, 2024 | finance.yahoo.comEditas to reduce workforce by 65%, announces departure of CMO Baisong MeiDecember 12, 2024 | markets.businessinsider.comEditas to reduce about 65% of its workforce over the next six monthsDecember 12, 2024 | reuters.comEditas Medicine Pivots Gene Editing Strategy, Cutting 65% of WorkforceDecember 12, 2024 | marketwatch.comEditas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two YearsDecember 12, 2024 | globenewswire.comWells Fargo Downgrades Editas Medicine (EDIT)December 12, 2024 | msn.comEditas Medicine downgraded to Equal Weight from Overweight at Wells FargoDecember 11, 2024 | markets.businessinsider.comHold Rating Maintained for Editas Medicine Amid Promising Developments and Safety ConcernsDecember 11, 2024 | markets.businessinsider.comEditas cut to equal weight by Wells Fargo over reni-cel positioningDecember 11, 2024 | msn.com12 Analysts Have This To Say About Editas MedicineDecember 11, 2024 | benzinga.comEditas Medicine Updates RUBY Trial with Promising ResultsDecember 11, 2024 | markets.businessinsider.comWells Fargo & Company Downgrades Editas Medicine (NASDAQ:EDIT) to Equal WeightWells Fargo & Company lowered Editas Medicine from an "overweight" rating to an "equal weight" rating and decreased their target price for the stock from $7.00 to $4.00 in a research report on Wednesday.December 11, 2024 | marketbeat.comEditas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual MeetingDecember 9, 2024 | globenewswire.com Get Editas Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter. Email Address EDIT Media Mentions By Week EDIT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EDIT News Sentiment▼0.340.44▲Average Medical News Sentiment EDIT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EDIT Articles This Week▼65▲EDIT Articles Average Week Get Editas Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ABIVAX Société Anonyme News Today Cryoport News Today Aura Biosciences News Today Organogenesis News Today KalVista Pharmaceuticals News Today Neumora Therapeutics News Today Prime Medicine News Today REGENXBIO News Today Monte Rosa Therapeutics News Today Valneva News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EDIT) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Editas Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Editas Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EDIT Stock Alerts